Whois & Analysis for keytruda.com

Pembrolizumab (formerly MK-3475 and lambrolizumab, trade name Keytruda) is a humanized antibody used in cancer immunotherapy.

It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells.

It targets the programmed cell death 1 (PD-1) receptor.

The drug was initially used to treat metastatic melanoma.

Immunotherapy is the "treatment of disease by inducing, enhancing, or suppressing an immune response".

Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

Programmed cell death protein 1, also known as PD-1 and CD279 (cluster of differentiation 279), is a cell surface receptor that plays an important role in down-regulating the immune system and promoting self tolerance by suppressing T cell inflammatory activity.

PD-1 is an immune checkpoint and guards against autoimmunity through a dual mechanism of promoting apoptosis (programmed cell death) in antigen specific T-cells in lymph nodes while simultaneously reducing apoptosis in regulatory T cells (anti-inflammatory, suppressive T cells).

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Not all tumors are cancerous; benign tumors do not spread to other parts of the body.

Possible signs and symptoms include a lump, abnormal bleeding, prolonged cough, unexplained weight loss and a change in bowel movements.

While these symptoms may indicate cancer, they may have other causes.

Over 100 types of cancers affect humans.